|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There were no relationship between HIF-1α-1772 C/T or -1790 G/A allele distribution and disease severity of NSCLC (P > 0.05).
|
22153809 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC.
|
24335195 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the consequences of inhibiting HIF activity in lung cancers, we deleted Hif-1alpha or Hif-2alpha in an established Kras(G12D)-driven murine NSCLC model.
|
20660313 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin.
|
26641474 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Specific HIF-1alpha polymorphisms were assessed in a series of patients with NSCLC: (a) the C to T transition at nucleotide 1744 (position 2028 according to sequence with accession number , which gives rise to Pro/Ser variation at codon 582), (b) the G to A nucleotide substitution at point 1790 (position 2046 according to sequence with accession number , which gives rise to Ala/Thr variation at codon 588), and (c) the dinucleotide GT repeat polymorphism in intron 13.
|
16837101 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variations on HIF1A gene are significantly associated with NSCLC outcomes in patients with early stage disease.
|
24567056 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of HIF-1alpha mRNA is associated with disease progression in NSCLC tissues, and is expected as a biomarker or therapeutic target.
|
19190516 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The roles of HIF-1α and c-Jun in development of resistance to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) with activating mutation of EGFR have not been explored.
|
29858032 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate the role of VEGF single nucleotide polymorphisms (SNPs), we examined the expression of several angiogenesis-related proteins [VEGF, hypoxia-inducible factor-1α (HIF-1α) and delta-like ligand 4 (Dll4)] and the spread of microvessels in resected non-small cell lung cancer (NSCLC).
|
23064377 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrate that in non-small cell lung cancer (NSCLC), p53 mutants exert a gain-of-function (GOF) effect on HIF-1, thus regulating a selective gene expression signature involved in protumorigenic functions.
|
30381462 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The interference of FAM201A impairs its suppression of miR-370, resulting in the upregulation of EGFR and HIF-1α and enhancement of radiosensitivity in NSCLC patients.
|
31298332 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, OLFM4/HIF-1α axis might be a potential therapeutic strategy for NSCLC.
|
30680718 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, HIF2α, but not HIF1α, was required for ALCL growth in vivo whereas the growth and metastasis potential of ALK-rearranged NSCLC required both HIF1α and HIF2α.
|
25193384 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1α/VEGF pathway in NSCLC with EGFR exon 19 deletions.
|
25748238 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results show that circPIP5K1A acted as a tumor promoter through a novel circPIP5K1A/miR-600/HIF-1α axis, which provides candidate markers and therapeutic targets for NSCLC.
|
31241217 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chloramphenicol Induces Autophagy and Inhibits the Hypoxia Inducible Factor-1 Alpha Pathway in Non-Small Cell Lung Cancer Cells.
|
30609861 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results demonstrated that the prognostic significance of HIF-1α should be validated in the context of EGFR status in NSCLC patients, and the gene and protein status of EGFR and HIF-1α will be important to help select patients most likely to derive the greatest clinical benefit from EGFR or HIF-1α targeted therapies.
|
20822827 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, the effects of hypoxia on the response of the NSCLC A549 cell line to the clinically relevant cytotoxic cisplatin were evaluated via regulating hypoxia inducible facor-1α (HIF-1α) and p53.
|
29971135 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that compound K suppresses NSCLC cell growth via HIF-1α mediated metabolic alteration, contributing to novel anticancer therapy by targeting glucose metabolism.
|
31078152 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the correlation between HIF1α and the sensitivity of human non-small cell lung cancer (NSCLC) cells to cisplatin has not been illuminated.
|
31169018 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
We demonstrate that in non-small cell lung cancer (NSCLC), p53 mutants exert a gain-of-function (GOF) effect on HIF-1, thus regulating a selective gene expression signature involved in protumorigenic functions.
|
30381462 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data reveal a novel EML4-ALK-HIF1α-HK2 cascade to enhance glucose metabolism in EML4-ALK-positive NSCLC.
|
27132509 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of miR-21 in tumor cell lines and clinical NSCLC tumor samples was positively correlated with hypoxia-inducible factor-1α and negatively correlated with PTEN.
|
30881046 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.
|
30665327 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Retinoblastoma binding protein 2 (RBP2) promotes HIF-1α-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
|
25162518 |
2014 |